Sign in

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

e-ISSN 1726-9148
p-ISSN 1726-913X
Authors GuideSubmit manuscript

Outline

https://doi.org/10.5812/ijem.3794

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes

Authors

Osamu Saito1,*, Takako Saito1, Shinji Asakura2, Tetsu Akimoto1, Makoto Inoue1, Yasuhiro Ando1, Shigeaki Muto1, Eiji Kusano1
1Department of Nephrology, Jichi Medical University, [email protected], Japan
2Oyama Suginoki Clinic, Japan
*Corresponding Author: Department of Nephrology, Jichi Medical University, Simotsuke, 329-0498, [email protected], Japan. Tel: +81-285587346. Fax: +81-285444869. Email: [email protected]
International Journal of Endocrinology and Metabolism:Vol. 10, issue 2; 464-469
Published online:Apr 20, 2012
Article type:Research Article
Received:Dec 13, 2011
Accepted:Feb 22, 2012
How to Cite:Saito O, Saito T, Asakura S, Akimoto T, Inoue M, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(2):. doi: https://doi.org/10.5812/ijem.3794

Abstract

Background:

Osteoporosis and chronic kidney disease are common conditions in older adults, and often occur concurrently. Bone disease is caused by increased bone turnover accompanying secondary hyperparathyroidism, and by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis, even in hemodialysis patients. Raloxifene is commonly used for the treatment of postmenopausal osteoporosis in the general population, and may be a treatment option for osteoporosis in hemodialysis patients. However, the effects of raloxifene in hemodialysis patients with type 2 diabetes have not been examined in detail.

Objectives:

This study was performed to investigate the effects of raloxifene on bone turnover markers and bone density in postmenopausal women with type 2 diabetes mellitus who were undergoing hemodialysis in Japan.

Patients and Methods:

The subjects were 60 female patients on maintenance hemodialysis (non-diabetic, n=30; diabetic, n=30). Raloxifene hydrochloride (60 mg) was administered to 14 diabetic patients and 14 non-diabetic patients for one year, and these patients were compared with control groups (no raloxifene) of 16 diabetic patients and 16 non-diabetic patients. Serum levels of N-terminal cross-linking telopeptide of type I collagen (NTx), bone alkaline phosphatase, and intact parathyroid hormone (iPTH) were measured, and bone density was determined by quantitative heel ultrasound at the speed of sound (SOS) in the calcaneus during this period.

Results:

There were no significant differences in the levels of bone turnover markers except for iPTH after treatment of diabetic and non-diabetic patients with raloxifene for one year. SOS increased after treatment with raloxifene, but was significantly decreased in the control groups. Treatment with raloxifene resulted in a significant decrease in NTx and a significant increase in SOS in both diabetic and non-diabetic patients. There were no significant differences between the diabetic and non-diabetic patients who received raloxifene.

Conclusions:

Treatment with raloxifene can suppress reduction in bone density in postmenopausal women with type 2 diabetes who are undergoing hemodialysis.

Highlights

KeywordsDiabetes MellitusType 2HemodialysisOsteoporosisRaloxifene

Full Text

Full text is available in PDF

Copyright

© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

5
Sep
2012

Effects of Raloxifene on Bone in Patients With Type 2 Diabetes

Itsuo Gorai
PDF

Gorai I. Effects of Raloxifene on Bone in Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(4):646-647. doi: https://doi.org/10.5812/ijem.6558

29
Sep
2012

Significant Effect of Raloxifene on Bone in Hemodialysis Patients

Pernille Ravn
PDF

Ravn P. Significant Effect of Raloxifene on Bone in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(4):636-637. doi: https://doi.org/10.5812/ijem.6251

29
Sep
2012

Safety of Raloxifene in Hemodialysis Patients

Didy Jacobsen
PDF

Jacobsen D. Safety of Raloxifene in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(4):638-639. doi: https://doi.org/10.5812/ijem.6285

29
Dec
2014

Comparison of bone mineral density in postmenopausal women with and without type 2 diabetes mellitus in Kermanshah

Karoun Shahebrahimi,
Maryam Rahmatinejad,
A’zam Sharifi,
Mehr Ali Rahimi,
Mohammad Hemati
PDF

Shahebrahimi K, Rahmatinejad M, Sharifi A, Rahimi MA, Hemati M. Comparison of bone mineral density in postmenopausal women with and without type 2 diabetes mellitus in Kermanshah. J Kermanshah Univ Med Sci. 2014;18(9):e74020. doi: https://doi.org/10.22110/jkums.v18i9.1488

12
Mar
2024
Evaluation of Bone Density Changes Before and After One Year of Denosumab (Prolia) Administration in Osteoporosis Patients

Evaluation of Bone Density Changes Before and After One Year of Denosumab (Prolia) Administration in Osteoporosis Patients

Mohsen G. Soroosh,
Atie Kazemi,
Mohsen Ahkiani
PDF

G. Soroosh M, Kazemi A, Ahkiani M. Evaluation of Bone Density Changes Before and After One Year of Denosumab (Prolia) Administration in Osteoporosis Patients. Ann Mil Health Sci Res. 2024;22(1):e143361. doi: https://doi.org/10.5812/amh-143361

More by these authors

Osamu SaitoPubMedScholar
Takako SaitoPubMedScholar
Shinji AsakuraPubMedScholar
Tetsu AkimotoPubMedScholar
Makoto InouePubMedScholar
Yasuhiro AndoPubMedScholar
Shigeaki MutoPubMedScholar
Eiji KusanoPubMedScholar

Find related work

PubMed
Google Scholar
Create citation alert
Download PDF857.17 KB
Import into EndNoteImport into BibTex
Share
Cited by
Metrics
Comments
Number of Comments:0